The comprehensive meta-analysis was designed to assess the efficacy and safety of ICIs in treating HER2-mutated NSCLC, thereby aiming to furnish a scientific foundation for clinical treatment plans. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.